SCHEMBL2413308

SCHEMBL2413308

CC(C)(C)OC(=O)C(C)(C)Sc1nc(COCc2ccc(-c3ccc(C(F)(F)F)cc3)cc2)cs1

nearest known ligand 0.41

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 1/20 0.41
▸ L3MBTL1 Q9Y468 1/20 0.41
▸ ALOX5 P09917 1/20 0.38
▸ PSEN1 P49768 1/20 0.38
▸ PPARD Q03181 4/20 0.38
▸ PPARG P37231 3/20 0.38
▸ PPARA Q07869 3/20 0.38
▸ TP53 P04637 6/20 0.37
▸ RXRA P19793 1/20 0.36
▸ NR1H2 P55055 1/20 0.36
▸ NR1H3 Q13133 1/20 0.36
▸ TLR7 Q9NYK1 1/20 0.36
▸ LMNA P02545 2/20 0.35
▸ FFAR1 O14842 1/20 0.35
▸ AR P10275 1/20 0.35
▸ POLB P06746 1/20 0.35
▸ MAPT P10636 1/20 0.35
▸ MAOB P27338 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2408451 0.89 PPARA (0.44) ALDH1A1L3MBTL1ALOX5PSEN1PPARD
SCHEMBL2410840 0.85 L3MBTL1 (0.34) L3MBTL1PPARATP53RXRALMNA
SCHEMBL2412511 0.83 RHOC (0.45) ALDH1A1L3MBTL1PPARDPPARGPPARA
SCHEMBL2410029 0.81 LMNA (0.54) ALDH1A1L3MBTL1PSEN1TP53LMNA
SCHEMBL2414332 0.81 PPARA (0.42) ALDH1A1L3MBTL1PPARDPPARGPPARA
SCHEMBL2415558 0.79 ALDH1A1 (0.41) ALDH1A1L3MBTL1PPARATP53LMNA
SCHEMBL2411182 0.77 PPARA (0.42) ALDH1A1L3MBTL1PPARGPPARATP53
SCHEMBL2415581 0.75 TP53 (0.39) ALDH1A1L3MBTL1TP53LMNAPOLB
SCHEMBL2414450 0.75 PPARA (0.40) ALDH1A1L3MBTL1PPARDPPARGPPARA
SCHEMBL2409692 0.74 PPARA (0.32) ALDH1A1L3MBTL1PPARA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8026370-B2 Peroxisome proliferator antagonist; hyperlipemia agents; arteriosclerosis; antiischemic agents MITSUBISHI TANABE PHARMA CORPORATION (JP) 2011-09-27 — — US claimed
US-8026370-B2 Peroxisome proliferator antagonist; hyperlipemia agents; arteriosclerosis; antiischemic agents MITSUBISHI TANABE PHARMA CORPORATION (JP) 2011-09-27 — — US disclosed
US-8026370-B2 Peroxisome proliferator antagonist; hyperlipemia agents; arteriosclerosis; antiischemic agents MITSUBISHI TANABE PHARMA CORPORATION (JP) 2011-09-27 — — US disclosed
US-8026370-B2 Peroxisome proliferator antagonist; hyperlipemia agents; arteriosclerosis; antiischemic agents MITSUBISHI TANABE PHARMA CORPORATION (JP) 2011-09-27 — — US disclosed
US-20080167307-A1 Carboxylic Acid Derivative Containing Thiazole Ring and Pharmaceutical Use Thereof MITSUBISHI PHAMA CORPORATION (JP) 2008-07-10 — — US disclosed
US-20080167307-A1 Carboxylic Acid Derivative Containing Thiazole Ring and Pharmaceutical Use Thereof MITSUBISHI PHAMA CORPORATION (JP) 2008-07-10 — — US disclosed
EP-1816128-A1 CARBOXYLIC ACID DERIVATIVE CONTAINING THIAZOLE RING AND PHARMACEUTICAL USE THEREOF Mitsubishi Pharma Corporation (JP) 2007-08-08 — — EP disclosed
EP-1816128-A1 CARBOXYLIC ACID DERIVATIVE CONTAINING THIAZOLE RING AND PHARMACEUTICAL USE THEREOF Mitsubishi Pharma Corporation (JP) 2007-08-08 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080167307-A1 Carboxylic Acid Derivative Containing Thiazole Ring and Pharmaceutical Use Thereof PPARA, PPARD, PPARG ALDH1A1 175/4885L3MBTL1 4700/4885ALOX5 664/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback